In November, Denner helped facilitate the sale of
hemophilia drug maker Bioverativ, for $ 11.6 billion, to Sanofi, a little more than a year after the company was spun out of Biogen, of which Denner is a director.
Not exact matches
A Shire buy would give it a way into the
hemophilia market, as well as more
drugs for combatting cancer and other illnesses.
In the early hours of Monday morning, French
drug giant Sanofi said it would buy
hemophilia drugmaker Bioverativ, a Biogen spinout that is less than a year old, for $ 11.6 billion.
The Food and
Drug Administration (FDA) has given Alnylam Pharmaceuticals the green light to relaunch clinical trials of its treatment for the bleeding disorder
hemophilia after pausing the studies after a patient death.
«When you have a population full of people that have
hemophilia you would charge incredibly high premiums because you know those
drugs are extremely expensive.
Biogen Idec (BIIB) sells a number of
drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of
drugs to treat
hemophilia.
«The first clinical investigation of this
drug in
hemophilia A patients with or without FVIII inhibitors has already been implemented, and Phase III studies are being planned to start in the near future.»
Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with
hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the
drugs that received the FDA's stamp of approval in 2017.
Dr. Brown's research publications have included: Self - cutting and sexual risk among adolescents in intesive psychiatric treatment; Promoting safer sex among HIV - positive youth with
hemophilia: Theory, intervention, and outcome; Predictors of retention among HIV /
hemophilia health care professionals; Impact of sexual abuse on the HIV - risk - related behavior of adolescents in intensive psychiatric treatment; Heroin use in adolescents and young adults admitted for
drug detoxification; and Children and adolescents living with HIV and AIDS: A review